Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 7, 2005, Pages 841-849

  Yuen, M F ^a   Chow, D H F ^a   Tsui, K ^a   Wong, B C Y ^a   Yuen, J C H ^a   Wong, D K H ^a   Lai, C L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; BIOCHEMICAL MARKER; LAMIVUDINE; METHIONINE; PEPTIDE; PLACEBO; TYROSINE;

ADULT; AGED; ARTICLE; CHINESE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE MUTATION; HEPATITIS B; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER HISTOLOGY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEROCONVERSION;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CHINA; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 16444362115     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02410.x     Document Type: Article

References (16)

1. Yuen MF, Lai CL. Debates in hepatitis: how to assess HBV DNA reductions in association with therapy. Viral Hepat Rev 1999; 5: 159-75.
2. Yuen MF, Lai CL. Treatment for chronic hepatitis B. Lancet Infect Dis 2001; 1: 232-41.
3. Yuen MF, Lai CL. Design for clinical trials in Far East. In: Lau, JYN, ed. HBV Protocol. Humana Press, NJ. 2003; 47-56.
4. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
5. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
6. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-8.
7. Dienstag JL, Goldin RD, Heathcote J, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
8. Kweon YO, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35: 749-55.
9. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
10. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after three years of therapy. Hepatology 2001; 33: 1527-32.
11. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
12. Allen MI, DesLauriers M, Andrews CW, et al. Identification and biologic characterization of mutations in HBV resistant to lamivudine. Hepatology 1998; 27: 1670-7.
13. Allen M, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for the detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37: 3338-47.
14. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
15. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors predicting hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91.
16. Suzuki Y, Arase Y, Ikeda K, et al. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 2003; 46: 164-70.